Copyright Reports & Markets. All rights reserved.

Global Central Nervous System Drugs Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Central Nervous System Drugs Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Central Nervous System Drugs Market Size Growth Rate by Product
      • 1.4.2 OTC
      • 1.4.3 Rx Drugs
    • 1.5 Market by End User
      • 1.5.1 Global Central Nervous System Drugs Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Retail Pharmacy
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Central Nervous System Drugs Market Size
      • 2.1.1 Global Central Nervous System Drugs Revenue 2014-2025
      • 2.1.2 Global Central Nervous System Drugs Sales 2014-2025
    • 2.2 Central Nervous System Drugs Growth Rate by Regions
      • 2.2.1 Global Central Nervous System Drugs Sales by Regions
      • 2.2.2 Global Central Nervous System Drugs Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Central Nervous System Drugs Sales by Manufacturers
      • 3.1.1 Central Nervous System Drugs Sales by Manufacturers
      • 3.1.2 Central Nervous System Drugs Sales Market Share by Manufacturers
      • 3.1.3 Global Central Nervous System Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.2 Central Nervous System Drugs Revenue by Manufacturers
      • 3.2.1 Central Nervous System Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Central Nervous System Drugs Revenue Share by Manufacturers (2014-2019)
    • 3.3 Central Nervous System Drugs Price by Manufacturers
    • 3.4 Central Nervous System Drugs Manufacturing Base Distribution, Product Types
      • 3.4.1 Central Nervous System Drugs Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Central Nervous System Drugs Product Type
      • 3.4.3 Date of International Manufacturers Enter into Central Nervous System Drugs Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Central Nervous System Drugs Sales by Product
    • 4.2 Global Central Nervous System Drugs Revenue by Product
    • 4.3 Central Nervous System Drugs Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Central Nervous System Drugs Breakdown Data by End User

    6 North America

    • 6.1 North America Central Nervous System Drugs by Countries
      • 6.1.1 North America Central Nervous System Drugs Sales by Countries
      • 6.1.2 North America Central Nervous System Drugs Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Central Nervous System Drugs by Product
    • 6.3 North America Central Nervous System Drugs by End User

    7 Europe

    • 7.1 Europe Central Nervous System Drugs by Countries
      • 7.1.1 Europe Central Nervous System Drugs Sales by Countries
      • 7.1.2 Europe Central Nervous System Drugs Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Central Nervous System Drugs by Product
    • 7.3 Europe Central Nervous System Drugs by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Central Nervous System Drugs by Countries
      • 8.1.1 Asia Pacific Central Nervous System Drugs Sales by Countries
      • 8.1.2 Asia Pacific Central Nervous System Drugs Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Central Nervous System Drugs by Product
    • 8.3 Asia Pacific Central Nervous System Drugs by End User

    9 Central & South America

    • 9.1 Central & South America Central Nervous System Drugs by Countries
      • 9.1.1 Central & South America Central Nervous System Drugs Sales by Countries
      • 9.1.2 Central & South America Central Nervous System Drugs Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Central Nervous System Drugs by Product
    • 9.3 Central & South America Central Nervous System Drugs by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Central Nervous System Drugs by Countries
      • 10.1.1 Middle East and Africa Central Nervous System Drugs Sales by Countries
      • 10.1.2 Middle East and Africa Central Nervous System Drugs Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Central Nervous System Drugs by Product
    • 10.3 Middle East and Africa Central Nervous System Drugs by End User

    11 Company Profiles

    • 11.1 Biogen
      • 11.1.1 Biogen Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Biogen Central Nervous System Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Biogen Central Nervous System Drugs Products Offered
      • 11.1.5 Biogen Recent Development
    • 11.2 Pfizer
      • 11.2.1 Pfizer Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Pfizer Central Nervous System Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Pfizer Central Nervous System Drugs Products Offered
      • 11.2.5 Pfizer Recent Development
    • 11.3 Teva
      • 11.3.1 Teva Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Teva Central Nervous System Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Teva Central Nervous System Drugs Products Offered
      • 11.3.5 Teva Recent Development
    • 11.4 Novartis
      • 11.4.1 Novartis Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Novartis Central Nervous System Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Novartis Central Nervous System Drugs Products Offered
      • 11.4.5 Novartis Recent Development
    • 11.5 Johnson & Johnson
      • 11.5.1 Johnson & Johnson Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Johnson & Johnson Central Nervous System Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Johnson & Johnson Central Nervous System Drugs Products Offered
      • 11.5.5 Johnson & Johnson Recent Development
    • 11.6 Eli Lilly
      • 11.6.1 Eli Lilly Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Eli Lilly Central Nervous System Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Eli Lilly Central Nervous System Drugs Products Offered
      • 11.6.5 Eli Lilly Recent Development
    • 11.7 Otsuka
      • 11.7.1 Otsuka Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Otsuka Central Nervous System Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Otsuka Central Nervous System Drugs Products Offered
      • 11.7.5 Otsuka Recent Development
    • 11.8 Merck
      • 11.8.1 Merck Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Merck Central Nervous System Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Merck Central Nervous System Drugs Products Offered
      • 11.8.5 Merck Recent Development
    • 11.9 AstraZeneca
      • 11.9.1 AstraZeneca Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 AstraZeneca Central Nervous System Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 AstraZeneca Central Nervous System Drugs Products Offered
      • 11.9.5 AstraZeneca Recent Development
    • 11.10 Novartis
      • 11.10.1 Novartis Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Novartis Central Nervous System Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Novartis Central Nervous System Drugs Products Offered
      • 11.10.5 Novartis Recent Development
    • 11.11 Shire

    12 Future Forecast

    • 12.1 Central Nervous System Drugs Market Forecast by Regions
      • 12.1.1 Global Central Nervous System Drugs Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Central Nervous System Drugs Revenue Forecast by Regions 2019-2025
    • 12.2 Central Nervous System Drugs Market Forecast by Product
      • 12.2.1 Global Central Nervous System Drugs Sales Forecast by Product 2019-2025
      • 12.2.2 Global Central Nervous System Drugs Revenue Forecast by Product 2019-2025
    • 12.3 Central Nervous System Drugs Market Forecast by End User
    • 12.4 North America Central Nervous System Drugs Forecast
    • 12.5 Europe Central Nervous System Drugs Forecast
    • 12.6 Asia Pacific Central Nervous System Drugs Forecast
    • 12.7 Central & South America Central Nervous System Drugs Forecast
    • 12.8 Middle East and Africa Central Nervous System Drugs Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Central Nervous System Drugs Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The central nervous system (CNS) is the part of thenervous system consisting of the brain and spinal cord. In this report, we study the drugs for central nervous system disease.
      The global Central Nervous System Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Central Nervous System Drugs market based on company, product type, end user and key regions.

      This report studies the global market size of Central Nervous System Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Central Nervous System Drugs in these regions.
      This research report categorizes the global Central Nervous System Drugs market by top players/brands, region, type and end user. This report also studies the global Central Nervous System Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Biogen
      Pfizer
      Teva
      Novartis
      Johnson & Johnson
      Eli Lilly 
      Otsuka
      Merck
      AstraZeneca
      Novartis
      Shire

      Market size by Product
      OTC
      Rx Drugs
      Market size by End User
      Hospital
      Retail Pharmacy

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Central Nervous System Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Central Nervous System Drugs market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Central Nervous System Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Central Nervous System Drugs submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Central Nervous System Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Central Nervous System Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now